Latest Breaking News On - Faron pharmaceuticals ltd - Page 11 : comparemela.com

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans -Today at 05:24 am

The following stocks are the leading risers and fallers on AIM in London on Tuesday. AIM - WINNERS Pantheon Resources PLC, up 13% at 15.31p, 12-month range 10.10p-136.00p. The.

City ofUnited kingdomMarie louise fjallskogSophie roseJay cheathamFaron pharmaceuticals ltdAlliance newsPantheon resourcesUs food drug administrationAlliance news ltdChief executive officer jay cheathamPharmaceuticals ltdDrug administrationOrphan drug designationChief medical officer marie louiseAll rights

Faron Pharmaceuticals Notice of Half-Year Financial Results

Faron Pharmaceuticals Notice of Half-Year Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMarkku jalkanenJo turnerphoneJames steelphoneJames obrienLifesci advisorsdaniel ferrymanagingNomadsandy jamiesonNorthjuha karttunenphoneCairn financial advisersFaron pharmaceuticals ltdFaron pharmaceuticals oyPeel huntFaron pharmaceuticalsjenniferc smith parkerhead of communicationsPharmaceuticals ltdFirst northChief executive officer

Bexmarilimab Plus SOC Continues to Show Early Activity in R/R AML and MDS

Bexmarilimab in combination with standard-of-care azacitidine or azacitidine plus venetoclax demonstrated early signs of efficacy in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

Eteläuomen läiMika kontroFaron pharmaceuticals ltdHelsinki university hospital comprehensive cancer centerInternational prognostic scoring systemRevised international prognostic scoring systemEuropean leukemianetBexmarilimab in combination with azacitidine or plus venetoclaxPatients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromeBexmab study

Faron to Hold Conference Call to Discuss New Positive

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage.

United statesJenniferc smith parkerSandy jamiesonJuha karttunenJo turnerChristopher goldenFaron pharmaceuticalsPeel huntHead of communicationsFaron pharmaceuticals ltdCairn financial advisersFirst northInvestor relations calendarCertified adviserNasdaq firstLondon stock exchange farn

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study. Conference Call and Webcast Wednesday, July 19, 2023, at 8:30 am ET. The live call may be accessed by dialing (877) 407-3982 for callers in the US and (201)

United statesChristopher goldenJuha karttunenSandy jamiesonJenniferc smith parkerJo turnerFaron pharmaceuticals ltdFaron pharmaceuticalsHead of communicationsPeel huntCairn financial advisersFirst northInvestor relations calendarCertified adviserNasdaq firstBiopharmaceutical company